Camptosar
Links shared publicly online about this topic
Enzon Opens Pediatric Study Of PEG-SN38
medicalnewstoday.com — “Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylat” View full resource at medicalnewstoday.com
Most Recently Shared on February 26, 2010 at 4:06 pm By:
Enzon Opens Pediatric Study Of PEG-SN38 http://mnt.to/3y9z #cancer
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MNT Cancer News
The latest cancer news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
